Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
For example, organizations like the American Diabetes Association suggest that GLP-1 therapies can be used early, even as first-line treatment in certain cases
Clinical trials have shown significant weight loss, with some patients losing up to 20% of their body weight
designated as a breakthrough therapy SPN-830 (Apomorphine Infusion Pump) Developer: Supernus/US WorldMeds/Brittania Modality: Small Molecule PDUFA Date: February 1, 2025 Indication/Description: Central nervous system disorders / Continuous subcutaneous infusion of the dopamine agonist apomorphine, used to treat motor fluctuations (OFF episodes) in adult Parkinson's disease patients Review Type: Standard Review Submission Date: August 1, 2024 Review Status: Experienced one RTF (Refuse to File) and two complete response letters
General disorders and administration site conditions The SOC of general disorders and administration site conditions encompassed 31 PTs from the FAERS database, predominantly related to administration site events
If you are interested in being part of that research, this is worth raising directly with your SheMed clinician
US$ 25.70
US$ 27.62
US$ 24.13
US$ 21.67
US$ 24.95
